Kro­nos Bio cuts a fifth of staff, ex­plores new dos­ing sched­ule for sol­id tu­mor drug

Kro­nos Bio is again re­sort­ing to cost-sav­ing mea­sures to ex­tend its cash run­way af­ter lay­ing off staff and reshuf­fling its pri­or­i­ties around four months ago.

Along with a planned 21% re­duc­tion in work­force, Kro­nos’ re­search repri­or­i­ti­za­tion should ex­tend its run­way through the sec­ond half of 2026, ac­cord­ing to a Thurs­day re­lease. The com­pa­ny had 99 full-time staff as of Sept. 30, per an SEC fil­ing, but in No­vem­ber it cut 19% of its em­ploy­ees to save cash. Kro­nos end­ed Sep­tem­ber last year with cash, cash equiv­a­lents and in­vest­ments worth $198.4 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER